Repligen Corporation · RGEN · FY2026 Q3 · Calendar Q4 2026

Repligen posts record Q3 revenue and raises 2026 guidance

The supplied analysis supports a constructive operating picture: record Q3 revenue, strong organic growth, raised 2026 guidance, and continued demand in proteins, chromatography, and analytics. The case still depends on converting the capital-equipment backlog, integrating BioLife, and sustaining Asia Pacific momentum.

Reported Before market openNASDAQHealthcare $11.44B market cap
80quality score

Earnings scorecard

Reported versus consensus
Reported EPS — Consensus $0.46
EPS surprise — Reported versus consensus
Reported revenue — Consensus $206.7M
Revenue surprise — Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -2.2% Event window
SPY move +0.5% Same window
Abnormal move -2.7% Stock minus SPY
Volume 0.5× Versus trailing sessions
Subsequent drift 0.0% Up to 20 sessions
RGENSPY benchmark

Ask FN2 about RGEN FY2026 Q3

Transcript, numbers and history already loaded
What drove RGEN's -2.2% move after FY2026 Q3 earnings?What changed in RGEN's guidance and outlook in FY2026 Q3?Give me the bull and bear case for RGEN after FY2026 Q3 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior quarter, BioLife has closed, Q3 revenue reached a record $209 million, capital-equipment orders reached a five-year high, and 2026 guidance was raised to an $848 million revenue midpoint.

Guidance delta

Management raised 2026 guidance to an $848 million revenue midpoint and 12–13% organic growth, with operating margin near 16%.

Key takeaways

  • Q3 revenue reached $209 million with 12.5% organic growth, according to the supplied transcript analysis.
  • BioLife closed in Q3 and is expected to contribute $24 million in Q4, with early synergies.
  • Capital-equipment orders reached a five-year high, but revenue recognition continues to lag orders.

Management priorities

  • Integrate BioLife and pursue expected 2027 EPS accretion.
  • Expand Asia Pacific operations, including training and innovation initiatives in South Korea and China.
  • Invest in AI, IT modernization, automation, and analytical products to support productivity and margin expansion.

Follow RGEN with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Company context

Snapshot as of publication

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand.…

Historical context

All RGEN earnings
+10.9%FY2026 Q2 · Calendar Q3 2026+6.3%FY2026 Q1 · Calendar Q2 2026

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
NVS Novartis AG FY2026 Q3 · Calendar Q4 2026 — +1.2% Novartis raises profit outlook as priority brands drive Q3 growth
RDY Dr. Reddy's Laboratories Limited FY2027 Q2 · Calendar Q4 2026 +24.0% -0.2% Dr. Reddy’s: margins improve as semaglutide rollout advances
DGX Quest Diagnostics Incorporated FY2026 Q3 · Calendar Q4 2026 +4.5% +1.8% Quest Diagnostics: growth broadens, but PAMA remains a headwind
ARGX argenx SE FY2026 Q3 · Calendar Q4 2026 — -1.6% argenx: VYVGART momentum and a broader late-stage pipeline

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the RGEN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-10-27T15:05:17.252500+00:00
  2. FN2 earnings calendar · 2026-10-27T01:23:15.065758+00:00
  3. Polygon adjusted daily market bars · 2026-10-27T15:20:43.304480+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-27T15:20:43.301869+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-27. For educational purposes only; not investment advice.